© Copyright Aridis Pharmaceuticals Inc. 2009-2015.

Site Map   |   Privacy Policy   |   Financial Conflict of Interest Policy


Aridis focuses on anti-infective alternatives to conventional antibiotics.


March 26th, 2015.  Aridis Pharmaceuticals Commences Phase 1 Clinical Study of Aerucin™ Monoclonal Antibody for Acute Pneumonia. (More)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

March 23rd, 2015.  Aridis Pharmaceuticals Appoints Paul-Andre de Lame, M.D., as Chief Medical Officer.  (More)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .January 6th, 2015.  Aridis Pharmaceuticals to Present at Biotech Showcase 2015.  (More)

.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

News


>> More News


In hospitals, 190 million doses of antibiotics are administered each day.  133 million courses of antibiotics are prescribed by doctors each year”

American College of Physicians

www.acponline.org [02 February 2013]

Our anti-infective drug candidates offer

substantial improvement over conventional antibiotics in: